Anti-Envelope protein (ZKA78)

Anti-Envelope protein [ZKA78], Recombinant, IgG1-LALA kappa, Human
SKU
ABAAb00780-10.16
Packaging Unit
200 μg
Manufacturer
Absolute Antibody

Availability: loading...
Price is loading...
CloneID: ZKA78

Heavy Chain modification: Fc Silenced

Antigen Long Description: mAb ZKA78 was selected from EBV-immortalized memory B cells derived from ZIKV-infected, DENV-naïve human donors based on its ability to bind Zika virus (ZIKV) Envelope protein and to neutralize ZIKV infection.

Buffer Composition: PBS with 0.02% Proclin 300.

Chimeric Use Statement: This reformatted human antibody was made using the variable domain sequences of the original Human IgG1 format, for improved compatibility with existing reagents, assays and techniques.

Available Custom Conjugation Options: AP, HRP, Fluorescein, APC, PE, Biotin Type A, Biotin Type B, Streptavidin, FluoroProbes 647H, Atto488, APC/Cy7, PE/Cy7

Uniprot Accession No.: Q91KX8

Specificity Statement: ZKA78 is specific for EDI/II domain of the ZIKV envelope (E) protein, and cross-reacts with the E protein from Dengue virus (DENV), which is highly homologous (also contains high sequence similarity with other flaviviruses such as yellow fever and west nile). ZKA78 showed significant binding (determined by ELISA) to the E proteins of ZIKV, DENV1-4 and the virus-like particles (VLPs) of DENV1-4. Flavivirus E proteins mediate fusion, with EDI being involved in conformational changes required for viral entry and EDII containing a fusion loop. ZIKV is a flavivirus that can be transmitted sexually, by the Aedes mosquito vector, or vertically to a developing fetus. Most cases of ZIKV infection are asymptomatic or manifest in mild symptoms, but in some cases ZIKV infection can result in Guillain-Barré Syndrome or congenital birth defects in developing fetuses.

Application Notes (Clone): ZKA78 is able to partially neutralize ZIKV infectivity (IC50 ~2863 ng/ml), and is capable of enhancing ZIKV/ infection of K526 cells via the antibody-dependent enhancement (ADE) effect. This antibody can also neutralize (IC50~ 266 ng/ml) and enhance (by ADE) DENV infection. Neutralization of ZIKV infection can be measured using a micro-neutralization FC-based assay, and binding/specificity to E protein can be studied by ELISA. DENV2-infected AG129 mice administered with ZKA78 results in death after 5 days.
More Information
SKU ABAAb00780-10.16
Manufacturer Absolute Antibody
Manufacturer SKU Ab00780-10.16
Package Unit 200 μg
Quantity Unit STK
Reactivity Virus
Clonality Recombinant
Application ELISA, Flow Cytometry, Neutralization
Isotype IgG1-LALA kappa
Host Human
Product information (PDF) Download
MSDS (PDF) Download